In general, can we extrapolate efficacy of biosimilars across all the disease states for which the originator has indication?

In general, can we extrapolate efficacy of biosimilars across all the disease states for which the originator has indication?

In general, can we extrapolate efficacy of biosimilars across all the disease states for which the originator has indication?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Joseph Markenson, MD

Joseph Markenson, MD

Department of Rheumatology
Department of Medicine
Hospital for Special Surgery, New York, NY
Attending Physician, Hospital for Special Surgery
Professor of Clinical Medicine, Weill Cornell Medical College